According to the latest report published by Credence Research, Inc. “Short Bowel Syndrome Market – (Drug Type – GLP-2, Glutamine, Growth Hormone and Other Drugs): Market Growth, Future Prospects and Competitive Analysis, 2017-2025,” the market was valued at US$ 315.1 Mn in 2016, and is expected to reach US$ 2,901.0 Mn by 2025, expanding at a CAGR of 27.5% from 2017 to 2025.
The report titled “Global Short Bowel Syndrome Market: 2018 Edition” examines the potential possibilities and significant trends in the Short Bowel Syndrome industry. The report provides a detailed analysis of the global Short Bowel Syndrome Market including the regional markets of North America, Europe, and the Asia Pacific. It focuses on the Short Bowel Syndrome Markets of the U.S., Canada, UK, India, and Australia. The report also assesses the commercial and residential service sector in the Short Bowel Syndrome industry.
Browse Full Report With Toc: https://www.credenceresearch.com/report/short-bowel-syndrome-market
Further, Porter’s Five Forces Analysis has been done for the global Short Bowel Syndrome industry. In-depth analysis of key market growth drivers and challenges and the major observable trends in the global Short Bowel Syndrome Market are also given in the report. The growth of the market has been projected taking into consideration various aspects like previous growth patterns, the current trends, the growth drivers, challenges and environmental conditions.
Region/Country Coverage
Company Coverage:
Merck KGaA, and Emmaus Life Sciences, Inc, Nutrinia Ltd, GlyPharma Therapeutics, OxThera, Ardelyx, Inc, and others.
Executive summary:
Short bowel syndrome is a group of complex diseases that occurs due to malfunction of a portion of small and/or large intestine. The individuals with short bowel syndrome exhibit poor absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals and other vital elements which leads to malnutrition, weight loss. However, in some cases, short bowel syndrome can lead to severe, disabling and life-threatening complications. There is no particular cure to this disorder however surgical removal (resection) of half or more of the small intestine is effective. Short bowel syndrome can lead to Crohn’s disease, injury or trauma to the small intestine. Such complications are making a significant contribution to the growth of the short bowel syndrome market. On the basis of drug the market is segmented into GLP-2, glutamine, growth hormone and others. GLP-2 currently holds the largest market in terms of drug in the short bowel syndrome market as it is marketed in U.S. and Europe under the brand name Gattex and Revestive in Europe and other international market. The drugs currently holds the orphan drug status, and the exclusivity of the drugs in the treatment of the short bowel syndrome would further draw huge revenue during the forecast period.
Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the global Short Bowel Syndrome Market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global Short Bowel Syndrome Market
- Leading company profiles reveal details of key Short Bowel Syndrome Market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the global Short Bowel Syndrome Market with 7-year forecasts
Reasons to buy
- What was the size of the global Short Bowel Syndrome Market by value in 2017?
- What will be the size of the global Short Bowel Syndrome Market in 2026?
- What factors are affecting the strength of competition in the global Short Bowel Syndrome Market?
- How has the market performed over the last five years?
- What are the main segments that make up the global Short Bowel Syndrome Market?
Request Customization: https://www.credenceresearch.com/request-for-customization/58584
Our Blog: http://www.technicaltop.com/
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph.: 1-800-361-8290
Website: http://www.credenceresearch.com
Follow Us: Twitter
LinkedIn @ https://us.linkedin.com/company/credenceresearch
The report titled “Global Short Bowel Syndrome Market: 2018 Edition” examines the potential possibilities and significant trends in the Short Bowel Syndrome industry. The report provides a detailed analysis of the global Short Bowel Syndrome Market including the regional markets of North America, Europe, and the Asia Pacific. It focuses on the Short Bowel Syndrome Markets of the U.S., Canada, UK, India, and Australia. The report also assesses the commercial and residential service sector in the Short Bowel Syndrome industry.
Browse Full Report With Toc: https://www.credenceresearch.com/report/short-bowel-syndrome-market
Further, Porter’s Five Forces Analysis has been done for the global Short Bowel Syndrome industry. In-depth analysis of key market growth drivers and challenges and the major observable trends in the global Short Bowel Syndrome Market are also given in the report. The growth of the market has been projected taking into consideration various aspects like previous growth patterns, the current trends, the growth drivers, challenges and environmental conditions.
Region/Country Coverage
- North America- United States & Canada
- Europe- United Kingdom
- APAC- India & Australia
Company Coverage:
Merck KGaA, and Emmaus Life Sciences, Inc, Nutrinia Ltd, GlyPharma Therapeutics, OxThera, Ardelyx, Inc, and others.
Executive summary:
Short bowel syndrome is a group of complex diseases that occurs due to malfunction of a portion of small and/or large intestine. The individuals with short bowel syndrome exhibit poor absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals and other vital elements which leads to malnutrition, weight loss. However, in some cases, short bowel syndrome can lead to severe, disabling and life-threatening complications. There is no particular cure to this disorder however surgical removal (resection) of half or more of the small intestine is effective. Short bowel syndrome can lead to Crohn’s disease, injury or trauma to the small intestine. Such complications are making a significant contribution to the growth of the short bowel syndrome market. On the basis of drug the market is segmented into GLP-2, glutamine, growth hormone and others. GLP-2 currently holds the largest market in terms of drug in the short bowel syndrome market as it is marketed in U.S. and Europe under the brand name Gattex and Revestive in Europe and other international market. The drugs currently holds the orphan drug status, and the exclusivity of the drugs in the treatment of the short bowel syndrome would further draw huge revenue during the forecast period.
Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the global Short Bowel Syndrome Market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global Short Bowel Syndrome Market
- Leading company profiles reveal details of key Short Bowel Syndrome Market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the global Short Bowel Syndrome Market with 7-year forecasts
Reasons to buy
- What was the size of the global Short Bowel Syndrome Market by value in 2017?
- What will be the size of the global Short Bowel Syndrome Market in 2026?
- What factors are affecting the strength of competition in the global Short Bowel Syndrome Market?
- How has the market performed over the last five years?
- What are the main segments that make up the global Short Bowel Syndrome Market?
Request Customization: https://www.credenceresearch.com/request-for-customization/58584
Our Blog: http://www.technicaltop.com/
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph.: 1-800-361-8290
Website: http://www.credenceresearch.com
Follow Us: Twitter
LinkedIn @ https://us.linkedin.com/company/credenceresearch
No comments:
Post a Comment